Bioventus Inc - Class A

Bioventus delivered a sharply better-than-expected first quarter, posting non-GAAP EPS of $0.08 against a consensus estimate of $0.02, a beat of 250.88%, while revenue of $123.88 million edged past the $122.71 million consensus by 0.95%. Reported revenue fell 4.3% year over year, a decline tied almost entirely to the company's divestiture of its Advanced Rehabilitation Business at the end of 2024; strip out that transaction and organic revenue grew 5.0%, with all three business segments contributing positively. Pain Treatments, the largest segment at $58.92 million, benefited from double-digit demand growth for Durolane, its single-injection knee osteoarthritis therapy, while Surgical Solutions added 7.0% growth to $45.23 million on strong Ultrasonics capital equipment sales. The net loss attributable to Bioventus narrowed to $2.64 million from $4.89 million a year ago, and interest expense fell to $7.51 million from $10.34 million as debt reduction efforts gained traction. Management reiterated full-year 2025 guidance calling for net sales of $560 million to $570 million and non-GAAP EPS of $0.64 to $0.68, representing growth of 30.6% to 38.8%.